<DOC>
	<DOCNO>NCT02039947</DOCNO>
	<brief_summary>This multi-cohort , open label , Phase II study Dabrafenib ( GSK2118436 ) Trametinib ( GSK1120212 ) combination therapy subject BRAF mutation-positive melanoma metastasize brain . This study evaluate safety efficacy 4 cohort . Cohorts consist ; V600 E , D , K , R mutation , metastasis brain , symptomatic asymptomatic , without prior local ( brain ) therapy , without prior local ( brain ) therapy , range ECOG score 0-2 .</brief_summary>
	<brief_title>Study Evaluate Treatment Dabrafenib Plus Trametinib Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized Brain</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>ECOG Performance Status range 02 Histologically confirm cutaneous metastatic melanoma V600 E , K , D R. May systemic na√Øve receive two previous systemic treatment regimens metastatic melanoma . Must able undergo MRI least one measurable intracranial lesion specific criterion meet . Prior treatment BRAF inhibitor mitogenactivated protein/extracellular signalregulated kinase inhibitor . Anticancer therapy investigational anticancer therapy chemotherapy without delayed toxicity within treatment specific timeframe . Treatment stereotactic radiosurgery treatment wholebrain radiation within treatment specific timeframe . Any presence leptomeningeal disease parenchymal brain metastasis History another malignancy , exception may apply . A history evidence cardiovascular risk specific criterion meet A history current evidence/risk retinal vein occlusion retinal pigment epithelial detachment specific criterion meet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BRAF V600K mutation</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>BRAF V600R mutation</keyword>
	<keyword>BRAF V600D mutation</keyword>
	<keyword>BRAF V600E mutation</keyword>
	<keyword>Brain metastasis BRAF inhibitor</keyword>
	<keyword>Intracranial</keyword>
</DOC>